Outcome of Photodynamic Therapy Using NPe6 for Bronchogenic Carcinomas in Central Airways &amp;gt;1.0 cm in Diameter

Usuda, Jitsuo; Ichinose, Shuji; Ishizumi, Taichirou; Hayashi, Hiroki; Ohtani, Kazuhiro; Maehara, Sachio; Ono, Shoutarou; Honda, Hiroaki; Kajiwara, Naohiro; Uchida, Osamu; Tsutsui, Hidemitsu; Ohira, Tetsuya; Kato, Harubumi; Ikeda, Norihiko

doi:10.1158/1078-0432.ccr-09-2520

Cited by 96 publications

(83 citation statements)

References 37 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently Usuda et al . 216 reported a series of seventy cancer lesions < or =1.0 cm in diameter and 21 lesions >1.0 cm in diameter treated with NPe6-PDT. The complete response rates were 94.0% (66 of 70) and 90.4% (19 of 21), respectively.…”

Section: Clinical Pdtmentioning

confidence: 99%

Photodynamic therapy of cancer: An update

Agostinis

Berg

Cengel

et al. 2011

CA: A Cancer Journal for Clinicians

4,191

3,792

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative particularly in early-stage tumors. It can prolong survival in inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments. With a number of recent technological improvements, PDT has the potential to become integrated into the mainstream of cancer treatment.

show abstract

Section: Clinical Pdtmentioning

confidence: 99%

Photodynamic therapy of cancer: An update

Agostinis

Berg

Cengel

et al. 2011

CA: A Cancer Journal for Clinicians

4,191

3,792

View full text Add to dashboard Cite

show abstract

“…NPe6-based PDT achieved a complete response in 94% of lesions ≤1.0 cm (n = 70) and 90% for lesions >1.0 cm (n 21). 79 Additional photosensitizers are under development to attempt to increase the depth of penetration, reduce the length of photosensitizity, and reduce PDT toxicity.…”

Section: Future Directions For Pdtmentioning

confidence: 99%

Photodynamic Therapy for Lung Cancer and Malignant Pleural Mesothelioma

Simone

Cengel

2014

Seminars in Oncology

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a form of non-ionizing radiation therapy that uses a drug, called a photosensitizer, combined with light to produce singlet oxygen (1O2) that can exert anti-cancer activity through apoptotic, necrotic, or autophagic tumor cell death. PDT is increasingly being used to treat thoracic malignancies. For early-stage non-small cell lung cancer (NSCLC), PDT is primarily employed as an endobronchial therapy to definitively treat endobronchial or roentgenographically occult tumors. Similarly, patients with multiple primary lung cancers may be definitively treated with PDT. For advanced or metastatic NSCLC and small cell lung cancer (SCLC), PDT is primarily employed to palliate symptoms from obstructing endobronchial lesions causing airway compromise or hemoptysis. PDT can be used in advanced NSCLC to attempt to increase operability or to reduce the extent of operation required, and selectively to treat pleural dissemination intraoperatively following macroscopically complete surgical resection. Intraoperative PDT can be safely combined with macroscopically complete surgical resection and other treatment modalities for malignant pleural mesothelioma (MPM) to improve local control and prolong survival. This report reviews the mechanism of and rationale for using PDT to treat thoracic malignancies, details prospective and major retrospectives studies of PDT to treat NSCLC, SCLC, and MPM, and describes improvements in and future roles and directions of PDT.

show abstract

“…For endotracheal CTLC, many thermal ablation approaches have been developed to relieve the distressing breathlessness, cough and obstructive pneumonia and improve respiratory function and performance status, including photodynamic therapy [7,26], brachytherapy [20,21], laser therapy [6], airway stenting [22] and endobronchial cryosurgery [15]. Among patients with extratracheal CTLC, only a minority are candidates for surgery [12,16,30], and chemotherapy and external beam radiation therapy have not greatly affected patient outcomes [5,23].…”

Section: Discussionmentioning

confidence: 99%